Overall, this study demonstrates potent theranostic capabilities of the metal chelation-driven texaphyrin NPs, which, in combination with PSMA-targeting ligands, may enable PCa imaging and therapy. This evidence concerns the gene FOLH1 and posterior cortical atrophy.